Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genprex ( (GNPX) ) just unveiled an update.
On August 18, 2025, Genprex announced that it received notices of allowance for patents from both the U.S. and European Patent Offices for its Reqorsa® Gene Therapy in combination with PD-L1 and PD-1 antibodies, with patents expiring in 2037. This development supports Genprex’s Acclaim-3 clinical trial for small cell lung cancer, which has received FDA Fast Track and Orphan Drug Designations, potentially enhancing the company’s market position and stakeholder confidence.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for cancer and diabetes. The company is known for its lead drug candidate, Reqorsa® Gene Therapy, which targets cancer treatment through innovative combinations with immunotherapy drugs.
Average Trading Volume: 2,002,659
Technical Sentiment Signal: Sell
Current Market Cap: $7.1M
Find detailed analytics on GNPX stock on TipRanks’ Stock Analysis page.